D
Desiree Martin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 3
Citations - 786
Desiree Martin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: CISH & Cancer. The author has an hindex of 2, co-authored 3 publications receiving 508 citations.
Papers
More filters
Journal ArticleDOI
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez,Cristina Ivan,David Valdecanas,Xiaohong Wang,Heidi J. Peltier,Yuping Ye,Luiz H. Araujo,David P. Carbone,Konstantin Shilo,Dipak Giri,Kevin Kelnar,Desiree Martin,Ritsuko Komaki,Daniel R. Gomez,Sunil Krishnan,George A. Calin,Andreas G. Bader,James W. Welsh +17 more
TL;DR: The results suggest that delivery of miRNAs with standard therapies, such as XRT, may represent a novel therapeutic approach for lung cancer, and identify a novel mechanism by which tumor immune evasion is regulated by p53/miR-34/PDL1 axis.
Journal ArticleDOI
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.
David S. Hong,Yoon-Koo Kang,Mitesh J. Borad,Jasgit C. Sachdev,Samuel Ejadi,Ho Yeong Lim,Andrew Brenner,Keunchil Park,Jae-Lyun Lee,Tae-You Kim,Sang Joon Shin,Carlos Becerra,Gerald S. Falchook,Jay Stoudemire,Desiree Martin,Kevin Kelnar,Heidi J. Peltier,Vinicius Bonato,Andreas G. Bader,Susan Smith,Sinil Kim,Vincent O’Neill,Muhammad Shaalan Beg +22 more
TL;DR: Although the trial was closed early due to serious immune-mediated AEs that resulted in four patient deaths, dose-dependent modulation of relevant target genes provides proof-of-concept for miRNA-based cancer therapy.
Journal ArticleDOI
In vivo localization of miR-34 delivered via liposomal MRX34: chromogenic in situ hybridization (CISH) results in a preclinical model and liver biopsies from phase I patients.
TL;DR: A novel miRNA-based therapy has the potential to simultaneously treat central giant cell granuloma and Huntington's disease.